Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MGX | Common Stockc | Conversion of derivative security | +513K | +199.74% | 770K | Feb 13, 2024 | Direct | F1 | ||
transaction | MGX | Common Stock | Conversion of derivative security | +1.9M | 1.9M | Feb 13, 2024 | By Humboldt Fund I, LP | F1, F2 | |||
holding | MGX | Common Stock | 402K | Feb 13, 2024 | By Praxis Biotech LLC | F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MGX | Series A-2 Preferred Stock | Conversion of derivative security | $0 | -353K | -100% | $0.00* | 0 | Feb 13, 2024 | Common Stock | 202K | Direct | F1 | |
transaction | MGX | Series A-3 Preferred Stock | Conversion of derivative security | $0 | -120K | -100% | $0.00* | 0 | Feb 13, 2024 | Common Stock | 68.5K | Direct | F1 | |
transaction | MGX | Series A-4 Preferred Stock | Conversion of derivative security | $0 | -423K | -100% | $0.00* | 0 | Feb 13, 2024 | Common Stock | 242K | Direct | F1 | |
transaction | MGX | Series A-4 Preferred Stock | Conversion of derivative security | $0 | -2.06M | -100% | $0.00* | 0 | Feb 13, 2024 | Common Stock | 1.18M | By Humboldt Fund I, LP | F1, F2 | |
transaction | MGX | Series B Preferred Stock | Conversion of derivative security | $0 | -1.14M | -100% | $0.00* | 0 | Feb 13, 2024 | Common Stock | 655K | By Humboldt Fund I, LP | F1, F2 | |
transaction | MGX | Series B-1 Preferred Stock | Conversion of derivative security | $0 | -107K | -100% | $0.00* | 0 | Feb 13, 2024 | Common Stock | 61K | By Humboldt Fund I, LP | F1, F2 |
Id | Content |
---|---|
F1 | Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date. |
F2 | Represents securities held directly by Humboldt Fund I, LP. Humboldt Fund I, LP is solely managed by Humboldt Capital, LLC, which is in turn managed by Sebastian Bernales, Francisco Dopazo and Benjamin Quiroga. Each of Mr. Bernales, Dopazo and Quiroga expressly disclaims beneficial ownership of the securities held by Humboldt Fund I, LP, except to the extent of his pecuniary interest in such securities. |
F3 | Represents securities held directly by Praxis Biotech LLC. The Reporting Person disclaims Section 16 beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of any of the reported securities for purposes of Section 16 or any other purpose. |